| Drug Name |
Testosterone cypionate |
| Drug ID |
BADD_D02171 |
| Description |
Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. |
| Indications and Usage |
Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.[L1153] |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB13943
|
| KEGG ID |
D00957
|
| MeSH ID |
C016131
|
| PubChem ID |
441404
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
60870-0252; 64025-0021; 0009-0086; 0143-9726; 52536-625; 62756-016; 0409-6562; 70700-288; 46439-8736; 62991-3132; 48087-0096; 0143-9659; 69097-536; 69097-802; 70700-289; 0574-0827; 76420-065; 51927-0189; 73774-016; 0591-4128; 38779-0164; 46204-0371; 60722-3016; 47781-911; 62756-015; 69097-537; 0143-9005; 63629-8706; 70700-290; 71225-127; 0009-0027; 47781-910; 63187-647; 63629-8705; 0517-1830; 51927-2706; 65089-0049; 73301-010; 0009-0347; 49803-006; 51552-0104; 63275-9982; 82393-114; 62756-017; 0409-6557; 0574-0820; 71205-289; 22552-0010; 43647-678; 0009-0085; 0009-0417; 50090-4147 |
| UNII |
M0XW1UBI14
|
| Synonyms |
testosterone 17 beta-cypionate | testosterone cypionate | testosterone 17 beta-cyclopentanepropionate | testosterone 17 beta-cyclopentylpropionate | Depo-Testosterone | Depo-Testosterone Cypionate | deposteron | Duratest | Testa-C | Testex Elmu | Andronate | Depostomead |
